After finishing at $4.16 in the prior trading day, Adaptive Biotechnologies Corp (NASDAQ: ADPT) closed at $4.27, up 2.64%. In other words, the price has increased by $+0.1100 from its previous closing price. On the day, 1000989 shares were traded.
Ratios:
Our goal is to gain a better understanding of ADPT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.50 and its Current Ratio is at 4.66. In the meantime, Its Debt-to-Equity ratio is 0.32 whereas as Long-Term Debt/Eq ratio is at 0.29.
On January 05, 2023, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $15.
Piper Sandler Upgraded its Neutral to Overweight on December 21, 2022, whereas the target price for the stock was revised from $7.50 to $14.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 16 when PISKEL KYLE sold 259 shares for $4.13 per share. The transaction valued at 1,070 led to the insider holds 87,305 shares of the business.
SOOD NITIN sold 10,550 shares of ADPT for $68,997 on Aug 08. The Chief Commercial Officer, MRD now owns 214,808 shares after completing the transaction at $6.54 per share. On Aug 07, another insider, SOOD NITIN, who serves as the Chief Commercial Officer, MRD of the company, sold 5,652 shares for $6.78 each. As a result, the insider received 38,321 and left with 225,358 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADPT now has a Market Capitalization of 618.18M and an Enterprise Value of 348.35M. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.64 while its Price-to-Book (P/B) ratio in mrq is 2.01. Its current Enterprise Value per Revenue stands at 1.94 whereas that against EBITDA is -2.18.
Stock Price History:
Over the past 52 weeks, ADPT has reached a high of $9.17, while it has fallen to a 52-week low of $2.61. The 50-Day Moving Average of the stock is 4.3018, while the 200-Day Moving Average is calculated to be 5.5851.
Shares Statistics:
The stock has traded on average 1.41M shares per day over the past 3-months and 1.76M shares per day over the last 10 days, according to various share statistics. A total of 145.08M shares are outstanding, with a floating share count of 141.79M. Insiders hold about 2.27% of the company’s shares, while institutions hold 95.41% stake in the company. Shares short for ADPT as of Jan 31, 2024 were 8.81M with a Short Ratio of 6.23, compared to 9.46M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 6.09% and a Short% of Float of 7.81%.
Earnings Estimates
Its stock is currently analyzed by 6 different market analysts. On average, analysts expect EPS of -$0.35 for the current quarter, with a high estimate of -$0.33 and a low estimate of -$0.37, while EPS last year was -$0.4. The consensus estimate for the next quarter is -$0.33, with high estimates of -$0.31 and low estimates of -$0.34.
Analysts are recommending an EPS of between -$1.29 and -$1.37 for the fiscal current year, implying an average EPS of -$1.31. EPS for the following year is -$1.06, with 6 analysts recommending between -$0.65 and -$1.29.
Revenue Estimates
7 analysts predict $38.21M in revenue for the current quarter. It ranges from a high estimate of $40M to a low estimate of $34.8M. As of the current estimate, Adaptive Biotechnologies Corp’s year-ago sales were $37.65M, an estimated increase of 1.50% from the year-ago figure.
A total of 8 analysts have provided revenue estimates for ADPT’s current fiscal year. The highest revenue estimate was $183.4M, while the lowest revenue estimate was $170M, resulting in an average revenue estimate of $175.61M. In the same quarter a year ago, actual revenue was $170.28M, up 3.10% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $220.99M in the next fiscal year. The high estimate is $256.8M and the low estimate is $195.5M. The average revenue growth estimate for next year is up 25.80% from the average revenue estimate for this year.
